Arenicin-1 vs PACAP-38
Head-to-head comparison of Arenicin-1 (Arenicin-1) and PACAP-38 (Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Arenicin-1 | PACAP-38 |
|---|---|---|
| Category | Marine-Derived | Cognitive Enhancement |
| Full Name | Arenicin-1 | Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38) |
| Molecular Weight | 2079 Da | 4534 Da |
| Half-Life | n/a | minutes |
| Amino Acids | 21 | 38 aa |
| Typical Dose | n/a | 10-100 µg preclinical range |
| Route | preclinical | Intranasal |
| Purity | ≥98% | ≥98% |
| Studies Count | 76 | 650 |
| Research Status | Pre-clinical | Pre-clinical |
Arenicin-1 Benefits
- ✓antimicrobial
- ✓anti-biofilm
- ✓membrane-active
PACAP-38 Benefits
- ✓synaptic plasticity
- ✓BDNF upregulation
- ✓neuroprotection
- ✓memory consolidation
Arenicin-1 Dosing
bacterial infection|biofilm disruption
PACAP-38 Dosing
0.1-1 nmol ICV in rodents|10-100 µg intranasal in preclinical studies|single-dose or short repeated protocols
Arenicin-1 Side Effects
- ⚠Arenicola marina
PACAP-38 Side Effects
- ⚠headache-like effects
- ⚠flushing
- ⚠hypotension
Research Overview
Arenicin-1
Marine annelid peptide with strong preclinical antibacterial activity and a stable structural motif that is useful for peptide engineering.
PACAP-38
PACAP-38 is one of the most studied endogenous neuropeptides for protecting neurons from ischemic and excitotoxic damage. Preclinical literature also links it to hippocampal plasticity and learning-related signaling, including increased BDNF expression.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.